{"success":true,"data":{"pressRelease":{"id":"57660","rtpr_id":"nGNX2Zg8cd","ticker":"PLRZ","exchange":"NASDAQ","all_tickers":["PLRZ"],"title":"Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial","author":"Globe Newswire","published_at":"2026-06-08T13:25:00.132Z","article_body":"Raanana, Israel, June 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq:\nPLRZ) (the “Company” or “Polyrizon”), a development-stage biotech\ncompany specializing in the development of innovative intranasal hydrogels,\ntoday announced it has signed agreements with two additional U.S. clinical\nsites. This brings the total to three major contracted sites for its upcoming\nNASARIX™ (PL-14) clinical study.\n\nThese three sites represent the largest and most strategically important\ncenters in the Company’s planned multi-center clinical trial and are\nexpected to contribute the highest rates of patient enrollment. The study will\nevaluate the safety, tolerability, and efficacy of the NASARIX™ Allergy\nBlocker in patients with seasonal allergic rhinitis.\n\nThis progress follows the Company’s recent announcement of its first U.S.\nclinical site, which the Company believes shows strong execution of its\nclinical plan.\n\n“We are very encouraged by the rapid expansion of our clinical site network,\nparticularly with the addition of two highly experienced and high-enrollment\ncenters,” said Tomer Izraeli, CEO of Polyrizon. “We believe that securing\nthe three leading sites early positions us strongly for efficient patient\nrecruitment and timely study execution as we prepare to initiate our\nmulti-center clinical trial.”\n\nThe study, titled “Evaluation of the Efficacy, Safety, and Tolerability of\nPL-14 Allergy Blocker Compared to Saline Spray in Patients with Seasonal\nAllergic Rhinitis,” is designed as a multi-center trial in the United\nStates, with up to five clinical sites expected to participate.\n\nThe NASARIX™ investigational product is an intranasal hydrogel formulation\nintended to create a protective physical barrier in the nasal cavity to block\nairborne allergens at the point of entry, potentially offering a\nnon-pharmacological approach to allergy prevention.\n\nThe trial will be conducted in accordance with international Good Clinical\nPractice (GCP) standards and applicable regulatory requirements, supporting\nthe Company’s broader regulatory strategy.\n\nAbout Polyrizon\n\nPolyrizon is a development stage biotech company specializing in the\ndevelopment of innovative medical device hydrogels delivered in the form of\nnasal sprays, which form a thin hydrogel-based shield containment barrier in\nthe nasal cavity that can provide a barrier against viruses and allergens from\ncontacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and\nContain (TM), or C&C, hydrogel technology, comprised of a mixture of\nnaturally occurring building blocks, is delivered in the form of nasal sprays,\nand potentially functions as a “biological mask” with a thin shield\ncontainment barrier in the nasal cavity. Polyrizon are further developing\ncertain aspects of our C&C hydrogel technology such as the bioadhesion and\nprolonged retention at the nasal deposition site for intranasal delivery of\ndrugs. Polyrizon refers to its additional technology, which is in an earlier\nstage of pre-clinical development, that is focused on nasal delivery of active\npharmaceutical ingredients, or APIs, as Trap and Target, or T&T. For more\ninformation, please visit https://polyrizon-biotech.com.\n\nForward Looking Statements\n\nThis press release contains “forward-looking statements” within the\nmeaning of the Private Securities Litigation Reform Act of 1995 and other\nsecurities laws. Words such as “expects,” “anticipates,”\n“intends,” “plans,” “believes,” “seeks,” “estimates” and\nsimilar expressions or variations of such words are intended to identify\nforward-looking statements. For example, the Company is using forward-looking\nstatements when it discusses the timing and progress of its clinical trials\nand studies , how the new clinical sites are expected to contribute the\nhighest rates of patient enrolment and its belief that securing the three\nleading sites early positions it strongly for efficient patient recruitment\nand timely study execution as we prepare to initiate our multi-center clinical\ntrial.  Forward-looking statements are not historical facts, and are based\nupon management’s current expectations, beliefs and projections, many of\nwhich, by their nature, are inherently uncertain. Such expectations, beliefs\nand projections are expressed in good faith. However, there can be no\nassurance that management’s expectations, beliefs and projections will be\nachieved, and actual results may differ materially from what is expressed in\nor indicated by the forward-looking statements. Forward-looking statements are\nsubject to risks and uncertainties that could cause actual performance or\nresults to differ materially from those expressed in the forward-looking\nstatements. For a more detailed description of the risks and uncertainties\naffecting the Company, reference is made to the Company’s reports filed from\ntime to time with the Securities and Exchange Commission (“SEC”),\nincluding, but not limited to, the risks detailed in the Company’s Annual\nReport on Form 20-F for the fiscal year ended December 31, 2025 and\nsubsequent filings with the SEC. Forward-looking statements speak only as of\nthe date the statements are made. The Company assumes no obligation to update\nforward-looking statements to reflect actual results, subsequent events or\ncircumstances, changes in assumptions or changes in other factors affecting\nforward-looking information except to the extent required by applicable\nsecurities laws. If the Company does update one or more forward-looking\nstatements, no inference should be drawn that the Company will make additional\nupdates with respect thereto or with respect to other forward-looking\nstatements. References and links to websites have been provided as a\nconvenience, and the information contained on such websites is not\nincorporated by reference into this press release. Polyrizon is not\nresponsible for the contents of third-party websites.\n\nContacts:\n\nMichal Efraty\nInvestor Relations\nIR@polyrizon-biotech.com\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2Zg8cd","title":"Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial","author":"Globe Newswire","ticker":"PLRZ","created":"2026-06-08T13:25:00.132Z","tickers":["PLRZ"],"exchange":"NASDAQ","article_body":"Raanana, Israel, June 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq:\nPLRZ) (the “Company” or “Polyrizon”), a development-stage biotech\ncompany specializing in the development of innovative intranasal hydrogels,\ntoday announced it has signed agreements with two additional U.S. clinical\nsites. This brings the total to three major contracted sites for its upcoming\nNASARIX™ (PL-14) clinical study.\n\nThese three sites represent the largest and most strategically important\ncenters in the Company’s planned multi-center clinical trial and are\nexpected to contribute the highest rates of patient enrollment. The study will\nevaluate the safety, tolerability, and efficacy of the NASARIX™ Allergy\nBlocker in patients with seasonal allergic rhinitis.\n\nThis progress follows the Company’s recent announcement of its first U.S.\nclinical site, which the Company believes shows strong execution of its\nclinical plan.\n\n“We are very encouraged by the rapid expansion of our clinical site network,\nparticularly with the addition of two highly experienced and high-enrollment\ncenters,” said Tomer Izraeli, CEO of Polyrizon. “We believe that securing\nthe three leading sites early positions us strongly for efficient patient\nrecruitment and timely study execution as we prepare to initiate our\nmulti-center clinical trial.”\n\nThe study, titled “Evaluation of the Efficacy, Safety, and Tolerability of\nPL-14 Allergy Blocker Compared to Saline Spray in Patients with Seasonal\nAllergic Rhinitis,” is designed as a multi-center trial in the United\nStates, with up to five clinical sites expected to participate.\n\nThe NASARIX™ investigational product is an intranasal hydrogel formulation\nintended to create a protective physical barrier in the nasal cavity to block\nairborne allergens at the point of entry, potentially offering a\nnon-pharmacological approach to allergy prevention.\n\nThe trial will be conducted in accordance with international Good Clinical\nPractice (GCP) standards and applicable regulatory requirements, supporting\nthe Company’s broader regulatory strategy.\n\nAbout Polyrizon\n\nPolyrizon is a development stage biotech company specializing in the\ndevelopment of innovative medical device hydrogels delivered in the form of\nnasal sprays, which form a thin hydrogel-based shield containment barrier in\nthe nasal cavity that can provide a barrier against viruses and allergens from\ncontacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and\nContain (TM), or C&C, hydrogel technology, comprised of a mixture of\nnaturally occurring building blocks, is delivered in the form of nasal sprays,\nand potentially functions as a “biological mask” with a thin shield\ncontainment barrier in the nasal cavity. Polyrizon are further developing\ncertain aspects of our C&C hydrogel technology such as the bioadhesion and\nprolonged retention at the nasal deposition site for intranasal delivery of\ndrugs. Polyrizon refers to its additional technology, which is in an earlier\nstage of pre-clinical development, that is focused on nasal delivery of active\npharmaceutical ingredients, or APIs, as Trap and Target, or T&T. For more\ninformation, please visit https://polyrizon-biotech.com.\n\nForward Looking Statements\n\nThis press release contains “forward-looking statements” within the\nmeaning of the Private Securities Litigation Reform Act of 1995 and other\nsecurities laws. Words such as “expects,” “anticipates,”\n“intends,” “plans,” “believes,” “seeks,” “estimates” and\nsimilar expressions or variations of such words are intended to identify\nforward-looking statements. For example, the Company is using forward-looking\nstatements when it discusses the timing and progress of its clinical trials\nand studies , how the new clinical sites are expected to contribute the\nhighest rates of patient enrolment and its belief that securing the three\nleading sites early positions it strongly for efficient patient recruitment\nand timely study execution as we prepare to initiate our multi-center clinical\ntrial.  Forward-looking statements are not historical facts, and are based\nupon management’s current expectations, beliefs and projections, many of\nwhich, by their nature, are inherently uncertain. Such expectations, beliefs\nand projections are expressed in good faith. However, there can be no\nassurance that management’s expectations, beliefs and projections will be\nachieved, and actual results may differ materially from what is expressed in\nor indicated by the forward-looking statements. Forward-looking statements are\nsubject to risks and uncertainties that could cause actual performance or\nresults to differ materially from those expressed in the forward-looking\nstatements. For a more detailed description of the risks and uncertainties\naffecting the Company, reference is made to the Company’s reports filed from\ntime to time with the Securities and Exchange Commission (“SEC”),\nincluding, but not limited to, the risks detailed in the Company’s Annual\nReport on Form 20-F for the fiscal year ended December 31, 2025 and\nsubsequent filings with the SEC. Forward-looking statements speak only as of\nthe date the statements are made. The Company assumes no obligation to update\nforward-looking statements to reflect actual results, subsequent events or\ncircumstances, changes in assumptions or changes in other factors affecting\nforward-looking information except to the extent required by applicable\nsecurities laws. If the Company does update one or more forward-looking\nstatements, no inference should be drawn that the Company will make additional\nupdates with respect thereto or with respect to other forward-looking\nstatements. References and links to websites have been provided as a\nconvenience, and the information contained on such websites is not\nincorporated by reference into this press release. Polyrizon is not\nresponsible for the contents of third-party websites.\n\nContacts:\n\nMichal Efraty\nInvestor Relations\nIR@polyrizon-biotech.com\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-08T13:25:00.173122282Z","server_sent_at_ms":1780925100173},"received_at":"2026-06-08T13:25:00.228Z","source_url":null},"analysis":{"id":"47088","press_release_id":"57660","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Polyrizon has secured three major U.S. clinical sites for its upcoming NASARIX (PL-14) multi-center trial, adding two new agreements to its existing network.\n\nThe study will evaluate the safety, tolerability, and efficacy of the NASARIX Allergy Blocker in patients with seasonal allergic rhinitis, comparing it to saline spray.\n\nManagement views the rapid site expansion as a sign of strong execution, positioning the company for efficient patient recruitment and timely study initiation.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Clinical site expansion for NASARIX trial signals operational progress for Polyrizon."},"keyFigures":{"drugName":"NASARIX (PL-14)","phaseOfTrial":"Multi-center clinical trial (Phase not explicitly stated, likely Phase 2 or 3 based on 'multi-center' and 'efficacy' focus, but text only says 'clinical study')","customDimensions":{"total_planned_sites":5,"clinical_sites_secured":3}},"quotedText":"We are very encouraged by the rapid expansion of our clinical site network, particularly with the addition of two highly experienced and high-enrollment centers","namedEntities":{"people":[{"name":"Tomer Izraeli","role":"CEO"},{"name":"Michal Efraty","role":"Investor Relations"}],"products":["NASARIX","PL-14","NASARIX Allergy Blocker","Capture and Contain (C&C) hydrogel technology","Trap and Target (T&T)"],"companies":[{"name":"Polyrizon Ltd.","ticker":"PLRZ","relationship":"filer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Operational milestone in clinical trial setup (securing sites) rather than a binary regulatory decision or data readout. Positive for execution confidence but low immediate financial impact for a development-stage biotech."},"tickerRelevance":{"others":[],"primary":"PLRZ"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"operational_milestone","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Polyrizon has secured three major U.S. clinical sites for its upcoming NASARIX (PL-14) multi-center trial, adding two new agreements to its existing network.\n\nThe study will evaluate the safety, tolerability, and efficacy of the NASARIX Allergy Blocker in patients with seasonal allergic rhinitis, comparing it to saline spray.\n\nManagement views the rapid site expansion as a sign of strong execution, positioning the company for efficient patient recruitment and timely study initiation.","key_figures":{"drugName":"NASARIX (PL-14)","phaseOfTrial":"Multi-center clinical trial (Phase not explicitly stated, likely Phase 2 or 3 based on 'multi-center' and 'efficacy' focus, but text only says 'clinical study')","customDimensions":{"total_planned_sites":5,"clinical_sites_secured":3}},"named_entities":{"people":[{"name":"Tomer Izraeli","role":"CEO"},{"name":"Michal Efraty","role":"Investor Relations"}],"products":["NASARIX","PL-14","NASARIX Allergy Blocker","Capture and Contain (C&C) hydrogel technology","Trap and Target (T&T)"],"companies":[{"name":"Polyrizon Ltd.","ticker":"PLRZ","relationship":"filer"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-08T13:25:16.507Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"operational_milestone","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low"}},"durationMs":16261,"modelName":"george-droid-qwen-72b"}}